Table 3 Dependence of targeted PAH therapy on age
From: Monotherapy in patients with pulmonary arterial hypertension at four German PH centres
Baseline | ≤ 65 years | > 65 years | p value |
|---|---|---|---|
PAH therapy, 0–3 months | n = 59 | n = 72 | |
None | 7 (11.9%) | 7 (9.7%) | 0.046 |
Monotherapy | 31 (52.5) | 52 (72.2%) | |
Dual therapy | 15 (25.4%) | 12 (16.7%) | |
Triple therapy | 6 (10.2%) | 1 (1.4%) | |
n = 52 | n = 65 | ||
Monotherapy | 31 (59.6%) | 52 (80.0%) | 0.016 |
Dual and triple therapy | 21 (40.4%) | 13 (20.0%) | |
PAH therapy, 4–8 months | n = 57 | n = 68 | |
Monotherapy | 28 (49.1%) | 44 (64.7%) | 0.171 |
Dual therapy | 22 (38.6%) | 20 (29.4%) | |
Triple therapy | 7 (12.3%) | 4 (5.9%) | |
n = 57 | n = 68 | ||
Monotherapy | 28 (49.1%) | 44 (64.7%) | 0.079 |
Dual and triple therapy | 29 (50.9%) | 24 (35.3%) | |
PAH therapy, 9–15 months | n = 48 | n = 63 | |
Monotherapy | 19 (39.6%) | 31 (49.2%) | 0.296 |
Dual therapy | 22 (45.8%) | 28 (44.4%) | |
Triple therapy | 7 (14.6%) | 4 (6.3%) | |
n = 48 | n = 63 | ||
Monotherapy | 19 (39.6%) | 31 (49.2%) | 0.313 |
Dual and triple therapy | 31 (60.4%) | 32 (50.8%) |